Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Sanjay Shukla, MD
aTyr Pharma
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Atyr Pharma Investigative Site
Marseille, France
- Atyr Pharma Investigative Site
Rome, Italy
- Atyr Pharma Investigative Site
Nijmegen, Netherlands
- Atyr Pharma Investigative Site
Rochester, New York, United States
- Atyr Pharma Investigative Site
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Sept 2014
- Primary completion
- 14 Dec 2015
- Completion
- 14 Dec 2015
- Last update posted
- 11 Aug 2021
- Registered enrollment
- 20
- Registry id
- NCT02239224
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 11 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.